CA-POINT2WEB
Point2Web, your ultimate marketing powerhouse in creative, advertising, and performance marketing, is thrilled to announce its appointment as the first Agency Sales Partner in Europe for NewsBreak, America's leading platform for local news and information, with over 40 million monthly active users.
Together, Point2Web and NewsBreak are poised to deliver exceptional advertising solutions that deeply engage local audiences. This partnership aims to drive significant growth and performance for Point2Web clients by combining the strengths of both companies to create something truly groundbreaking. The collaboration is expected to foster innovation, enhance service excellence, and achieve positive results for NewsBreak’s local users and their communities across America.
By utilizing NewsBreak's innovative technology and unrivaled local footprint, brands can revolutionize their local and targeted advertising and help direct resources where they are needed most. Point2Web's industry-leading expertise will further enable clients to amplify their advertising impact on an unprecedented scale. The collaboration will be particularly beneficial to advertisers in insurance, finance, travel, home improvement, e-commerce, and casual gaming, among others.
Partnership Highlights:
- Extended Reach: Point2Web clients will now have access to NewsBreak's 40 million users across the U.S., significantly enhancing the impact of their advertising campaigns. This access ensures advertisers can reach a vast yet highly engaged user base.
- Innovative Solutions: The partnership brings NewsBreak's use of new technology to Point2Web's clientele.
- Global Expertise, Local Impact: Point2Web's global presence and deep expertise in performance networks, combined with NewsBreak's robust local information platform, ensures a targeted and effective advertising strategy that will resonate with local communities. This synergy enables advertisers to craft messages that are both globally informed and locally relevant.
- Fostering Innovation and Achieving Success: Both Point2Web and NewsBreak share a strong commitment to innovation, excellence in service, and achieving positive results for their stakeholders. This partnership is a testament to their joint vision of pushing the boundaries of what is possible in digital advertising.
“Through our partnership with NewsBreak, we’re not just expanding the digital footprint of our clients; we’re providing them with the tools and platforms necessary to achieve unprecedented levels of engagement and success in their advertising campaigns,” said Valentine Kovalenko, COO at Point2Web. “This collaboration is a testament to our unwavering commitment to innovation and excellence in service. NewsBreak’s audience is highly engaged and of high quality, which ensures that our clients' ads reach a valuable and responsive demographic.”
“We are thrilled to partner with Point2Web, whose global expertise and innovative approach align perfectly with our mission to create a local media ecosystem where information is readily available and easily accessible," said Ryan Ludlow, General Manager of NewsBreak Advertising. "By leveraging our cutting-edge new technology and working with strategic partners like Point2Web, we remain dedicated to enhancing advertiser success and maintaining our focus on ad quality.”
For more information about this partnership and how it can benefit your advertising strategies, please visit our website.
About Point2Web
Point2Web is a global advertising agency that specializes in performance marketing and exceptional creative development. We unite media buying, creative development, and agency access to top-tier ad platforms to provide a powerful blend of services, expertise, and exclusive partnerships around the globe.
Our dedication to excellence and innovation is evident in every project we undertake. Our brand is anchored by our core values: reliability, mutual trust, top-tier service, steadfast commitment, and unending innovation. As we expand our horizons, Point2Web is committed to transparency, integrity, and achieving superior results for our clients.
We redefine the standard with our forward-thinking mindset and the latest in technology, setting new benchmarks in creativity. With a footprint in nine countries, advertisers and publishers worldwide can benefit from our unwavering commitment to driving their growth.
About NewsBreak
NewsBreak is the leading platform for local news and information in the United States, providing users with the local news and information they want and need in a digital form. By using cutting-edge technology that learns users’ preferences to curate tailored content for them, NewsBreak gathers community-focused news and information from over 10,000 sources in a timely, accessible, and easy-to-use way at no cost to users. NewsBreak is bridging the gap between new technology and traditional local media, offering an innovative digital solution that benefits everyone, from individual users and their communities to businesses across America.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729481955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom